An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Current cancer detection methods struggle with sensitivity for minimal residual disease (MRD) and early recurrence.
• Early detection of MRD is crucial for effective cancer treatment and improved patient outcomes.

Purpose of the Study:

• To develop and validate a novel, highly sensitive liquid biopsy approach for early cancer detection.
• To enhance the detection capabilities for minimal residual disease (MRD) and circulating tumor DNA (ctDNA).

Main Methods:

• Utilized an integrated comprehensive droplet digital detection (IC3D) digital PCR system.
• Combined microfluidic droplet partitioning, multiplex PCR chemistry, and rapid 3D, large-volume droplet counting.
• Demonstrated detection of KRAS G12D mutants in patient samples and spiked wild-type backgrounds.

Main Results:

• Achieved 100% specificity in detecting KRAS G12D mutants.
• Reached a sensitivity of 0.00125-0.005% for oncogenic KRAS G12D mutant alleles with 0% false positive rate.
• Demonstrated 50 to 1000x greater sensitivity compared to commercial ddPCR and qPCR platforms.

Conclusions:

• The IC3D ddPCR system offers unprecedented sensitivity for detecting ultra-rare cancer genomic targets.
• This technology enables direct detection of circulating tumor cells and analysis of total tumor DNA, improving clinical utility.
• The novel approach provides a powerful tool for monitoring MRD and enabling earlier cancer intervention.